American Pharma’s Sickly While China’s Life Sciences Boom
American healthcare giants are reporting declining sales and profits while China’s life sciences sector is booming. Chinese firms now account for 32% of global drug-licensing deals and are producing half of all new molecules entering human trials. The tables have turned in pharmaceutical innovation.










































